Keywords

• ent-Ertugliflozin
• 2222717-52-2
• C22H25ClO7

Quick Details

• ProName: ent-Ertugliflozin;2222717-52-2
• CasNo: 2222717-52-2
• Appearance: White to off white powder
• Application: experiment research
• DeliveryTime: prompt delivery
• PackAge: Food bags, aluminum foil bags
• Port: Shenzhen/hongkong
• ProductionCapacity: 5000 Gram/Year
• Purity: 99%+ HPLC
• Storage: cool and dry
• Transportation: DHL,EMS,TNT,UPS,EMS,by air,by sea;
• LimitNum: 10 Milligram
• Moisture Content: 0.1%
• Impurity: 0.1%

Superiority

• Advantages

   

• High Purity Guarantee: Confirmed by HPLC with a purity of ≥99.0%, and the structure is verified by NMR (1H, 13C), HRMS, and elemental analysis, providing a reliable basis for studies related to Ertugliflozin.

• Good Stability: Stable for 36 months under storage conditions of -20℃ in the dark and sealed. The degradation rate is less than 0.2% in common solvents, ensuring good repeatability of experimental results.

•  

Details

ent-Ertugliflozin; 2222717-52-2

Product Information

• English Name: ent-Ertugliflozin

• English Alias: (1R,2R,3R,4S,5R)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol

• CAS No.: 2242891-20-7

• Molecular Formula: C??H??ClO?

• Molecular Weight: 436.88

Applications

• Drug Research: Used as a reference substance for the separation study of Ertugliflozin enantiomers, facilitating the development of chiral drug analysis methods.

• Quality Control: Used for the quality inspection of Ertugliflozin API and formulations, controlling the content of related impurities to ensure that the drug quality meets the standards.

• Mechanism Exploration: In the study of drug action mechanisms, it helps analyze the metabolic differences and biological activity differences of its enantiomers in vivo.

Background Description
Ertugliflozin is a drug for treating type 2 diabetes, which reduces blood sugar by inhibiting renal glucose reabsorption. ent-Ertugliflozin, as its enantiomer, may be produced during the synthesis process. The presence of enantiomers may affect the pharmacokinetics, pharmacodynamics, and safety of the drug. With the in-depth research on chiral drugs, the study of ent-Ertugliflozin helps to comprehensively understand the properties of Ertugliflozin and ensure the safety and effectiveness of medication.

Research Status

• Detection Technology: Supercritical fluid chromatography (SFC) - MS/MS or high-performance liquid chromatography with chiral columns are used to effectively separate ent-Ertugliflozin from Ertugliflozin, with a limit of detection of 0.002 ng/mL.

• Activity Research: In vitro cell experiments show that the affinity of ent-Ertugliflozin for the SGLT2 receptor is lower than that of Ertugliflozin, and its hypoglycemic activity is weaker, but it may have other potential biological activities, and related research is ongoing.

• Metabolism Research: Animal experiments have found that the metabolic pathways of ent-Ertugliflozin in vivo partially overlap with those of Ertugliflozin, but the metabolic rates and products are different, and the specific mechanisms remain to be further clarified.